CP-690,550 and Midazolam Drug-Drug Interaction Study

A Phase 1, Randomized, 2-Way Crossover, Multiple Dose, Open Label Study Of The Effect Of CP-690,550 On Midazolam Pharmacokinetics In Healthy Volunteers

CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.

Inclusion Criteria:

• Healthy male and/or female (non-child bearing potential) subjects

Exclusion Criteria:

• Clinically significant infections within the past 3 months
• History of previously untreated infection with Mycobacterium tuberculosis
• Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus